Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1988 Aug;62(8):2622–2628. doi: 10.1128/jvi.62.8.2622-2628.1988

Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

P L Nara 1, W G Robey 1, S W Pyle 1, W C Hatch 1, N M Dunlop 1, J W Bess Jr 1, J C Kelliher 1, L O Arthur 1, P J Fischinger 1
PMCID: PMC253692  PMID: 3392769

Abstract

Repeated immunizations of goats, horses, or chimpanzees with envelope glycoprotein gp120 isolated from human immunodeficiency virus type 1 (HIV-1) resulted in type-specific neutralizing-antibody responses, which began to decay approximately 20 days following the administration of antigen. This was true repeatedly for serum samples from animals hyperimmunized with gp120s from either the HTLV-IIIB (IIIB) or the envelope-divergent HTLV-IIIRF (RF) HIV-1 isolates. Animals previously immunized with the IIIB gp120 were then inoculated with purified RF gp120. The first response in these animals was an anamnestic resurgence of neutralizing antibody to IIIB without detectable neutralizing antibody for RF. However, with later RF gp120 boosts, the IIIB neutralizing-antibody titers fell and an RF type-specific neutralizing-antibody response developed. When assessed with other HIV-1 variants, no group-specific neutralizing antibody was seen in any of the vaccination protocols evaluated. These results will pose real obstacles in the development of an effective vaccine for HIV.

Full text

PDF
2622

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alizon M., Wain-Hobson S., Montagnier L., Sonigo P. Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients. Cell. 1986 Jul 4;46(1):63–74. doi: 10.1016/0092-8674(86)90860-3. [DOI] [PubMed] [Google Scholar]
  2. Arthur L. O., Pyle S. W., Nara P. L., Bess J. W., Jr, Gonda M. A., Kelliher J. C., Gilden R. V., Robey W. G., Bolognesi D. P., Gallo R. C. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8583–8587. doi: 10.1073/pnas.84.23.8583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Benn S., Rutledge R., Folks T., Gold J., Baker L., McCormick J., Feorino P., Piot P., Quinn T., Martin M. Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. Science. 1985 Nov 22;230(4728):949–951. doi: 10.1126/science.2997922. [DOI] [PubMed] [Google Scholar]
  4. Chanh T. C., Dreesman G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986 Nov;5(11):3065–3071. doi: 10.1002/j.1460-2075.1986.tb04607.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dahl K., Martin K., Miller G. Differences among human immunodeficiency virus strains in their capacities to induce cytolysis or persistent infection of a lymphoblastoid cell line immortalized by Epstein-Barr virus. J Virol. 1987 May;61(5):1602–1608. doi: 10.1128/jvi.61.5.1602-1608.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fischinger P. J., Sch5AAFER W., Bolognesi D. P. Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus. Virology. 1976 May;71(1):169–184. doi: 10.1016/0042-6822(76)90103-3. [DOI] [PubMed] [Google Scholar]
  7. Hahn B. H., Shaw G. M., Arya S. K., Popovic M., Gallo R. C., Wong-Staal F. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature. 1984 Nov 8;312(5990):166–169. doi: 10.1038/312166a0. [DOI] [PubMed] [Google Scholar]
  8. Hahn B. H., Shaw G. M., Taylor M. E., Redfield R. R., Markham P. D., Salahuddin S. Z., Wong-Staal F., Gallo R. C., Parks E. S., Parks W. P. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science. 1986 Jun 20;232(4757):1548–1553. doi: 10.1126/science.3012778. [DOI] [PubMed] [Google Scholar]
  9. Harada S., Kobayashi N., Koyanagi Y., Yamamoto N. Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-III B, LAV, and ARV). Virology. 1987 Jun;158(2):447–451. doi: 10.1016/0042-6822(87)90219-4. [DOI] [PubMed] [Google Scholar]
  10. Hunsmann G., Moennig V., Schäfer W. Properties of mouse leukemia viruses. IX. Active and passive immunization of mice against Friend leukemia with isolated viral GP71 glycoprotein and its corresponding antiserum. Virology. 1975 Jul;66(1):327–329. doi: 10.1016/0042-6822(75)90203-2. [DOI] [PubMed] [Google Scholar]
  11. Jarrett W., Jarrett O., Mackey L., Laird H., Hood C., Hay D. Vaccination against feline leukaemia virus using a cell membrane antigen system. Int J Cancer. 1975 Jul 15;16(1):134–141. doi: 10.1002/ijc.2910160115. [DOI] [PubMed] [Google Scholar]
  12. Kishimoto T., Ishizaka K. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J Immunol. 1973 Oct;111(4):1194–1205. [PubMed] [Google Scholar]
  13. Krohn K., Robey W. G., Putney S., Arthur L., Nara P., Fischinger P., Gallo R. C., Wong-Staal F., Ranki A. Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. Proc Natl Acad Sci U S A. 1987 Jul;84(14):4994–4998. doi: 10.1073/pnas.84.14.4994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lasky L. A., Groopman J. E., Fennie C. W., Benz P. M., Capon D. J., Dowbenko D. J., Nakamura G. R., Nunes W. M., Renz M. E., Berman P. W. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science. 1986 Jul 11;233(4760):209–212. doi: 10.1126/science.3014647. [DOI] [PubMed] [Google Scholar]
  15. Lewis M. G., Mathes L. E., Olsen R. G. Protection against feline leukemia by vaccination with a subunit vaccine. Infect Immun. 1981 Dec;34(3):888–894. doi: 10.1128/iai.34.3.888-894.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Marx P. A., Pedersen N. C., Lerche N. W., Osborn K. G., Lowenstine L. J., Lackner A. A., Maul D. H., Kwang H. S., Kluge J. D., Zaiss C. P. Prevention of simian acquired immune deficiency syndrome with a formalin-inactivated type D retrovirus vaccine. J Virol. 1986 Nov;60(2):431–435. doi: 10.1128/jvi.60.2.431-435.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nara P. L., Hatch W. C., Dunlop N. M., Robey W. G., Arthur L. O., Gonda M. A., Fischinger P. J. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses. 1987 Fall;3(3):283–302. doi: 10.1089/aid.1987.3.283. [DOI] [PubMed] [Google Scholar]
  18. Nara P. L., Robey W. G., Arthur L. O., Asher D. M., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C., Fischinger P. J. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses. J Virol. 1987 Oct;61(10):3173–3180. doi: 10.1128/jvi.61.10.3173-3180.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nara P. L., Robey W. G., Gonda M. A., Carter S. G., Fischinger P. J. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1987 Jun;84(11):3797–3801. doi: 10.1073/pnas.84.11.3797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Plata F., Autran B., Martins L. P., Wain-Hobson S., Raphaël M., Mayaud C., Denis M., Guillon J. M., Debré P. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 1987 Jul 23;328(6128):348–351. doi: 10.1038/328348a0. [DOI] [PubMed] [Google Scholar]
  21. Putney S. D., Matthews T. J., Robey W. G., Lynn D. L., Robert-Guroff M., Mueller W. T., Langlois A. J., Ghrayeb J., Petteway S. R., Jr, Weinhold K. J. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science. 1986 Dec 12;234(4782):1392–1395. doi: 10.1126/science.2431482. [DOI] [PubMed] [Google Scholar]
  22. Pyle S. W., Dubois G. C., Robey W. G., Bess J. W., Jr, Fischinger P. J., Arthur L. O. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF. J Virol. 1988 Jul;62(7):2258–2264. doi: 10.1128/jvi.62.7.2258-2264.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Robey W. G., Arthur L. O., Matthews T. J., Langlois A., Copeland T. D., Lerche N. W., Oroszlan S., Bolognesi D. P., Gilden R. V., Fischinger P. J. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7023–7027. doi: 10.1073/pnas.83.18.7023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schäfer W., Schwarz H., Thiel H. J., Fischinger P. J., Bolognesi D. P. Properties of mouse leukemia viruses. XIV. Prevention of spontaneous AKR leukemia by treatment with group-specific antibody against the major virus gp71 glycoprotein. Virology. 1977 Nov;83(1):207–210. doi: 10.1016/0042-6822(77)90224-0. [DOI] [PubMed] [Google Scholar]
  25. Starcich B. R., Hahn B. H., Shaw G. M., McNeely P. D., Modrow S., Wolf H., Parks E. S., Parks W. P., Josephs S. F., Gallo R. C. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell. 1986 Jun 6;45(5):637–648. doi: 10.1016/0092-8674(86)90778-6. [DOI] [PubMed] [Google Scholar]
  26. Waldmann H., Lefkovits I., Quintáns J. Limiting dilution analysis of helper T-cell function. Immunology. 1975 Jun;28(6):1135–1148. [PMC free article] [PubMed] [Google Scholar]
  27. Walker B. D., Chakrabarti S., Moss B., Paradis T. J., Flynn T., Durno A. G., Blumberg R. S., Kaplan J. C., Hirsch M. S., Schooley R. T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987 Jul 23;328(6128):345–348. doi: 10.1038/328345a0. [DOI] [PubMed] [Google Scholar]
  28. Weiss R. A., Clapham P. R., Cheingsong-Popov R., Dalgleish A. G., Carne C. A., Weller I. V., Tedder R. S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985 Jul 4;316(6023):69–72. doi: 10.1038/316069a0. [DOI] [PubMed] [Google Scholar]
  29. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986 Dec 11;324(6097):572–575. doi: 10.1038/324572a0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES